Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
GlaxoSmithKline (GSK) yesterday said that it would pay $229 million (?149 million) to eight US states to settle lawsuits over improper marketing of its diabetes drug Avandia.
The latest settlement on Avandia comes after GSK agreed to pay $3 billion last year to the US government over marketing drugs for unapproved uses, not providing Avandia safety data to the US Food and Drug Administration.
http://www.domain-b.com/companies/companies_g/GlaxoSmithKline/20130725_diabetes.html
The latest settlement on Avandia comes after GSK agreed to pay $3 billion last year to the US government over marketing drugs for unapproved uses, not providing Avandia safety data to the US Food and Drug Administration.
http://www.domain-b.com/companies/companies_g/GlaxoSmithKline/20130725_diabetes.html